🚨Trade Alert 🚨 NNVC

🚨Trade Alert 🚨 NNVC͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ Moderna was a Huge Biotech Winner Out of the Pandemic and Now [NanoViricides, Inc. (NYSE: NNVC)]( May Be the Next Compelling Biotech Stock to Keep an Eye on as Clinical Trials for the Company HAVE NOW BEGUN! Greetings All, The [World Health Organization (WHO)]( recently declared an end to the emergency phase of the COVID-19 pandemic. While many think this is good news, WHO’s director-general, Tedros Adhanom Ghebreyesus, emphasized that this declaration does not mean COVID-19 is no longer a threat! “The worst thing any country could do now is to use this news as a reason to let down its guard, to dismantle the systems it has built, or to send the message to its people that COVID-19 is nothing to worry about,” he said. Many immunocompromised and older people are still terrified of COVID, and the virus is still going strong and killing people. We are not out of the woods yet and this means companies in the fight against the virus are still more important than ever. Moderna (NASDAQ: MRNA) proved just how lucrative the opportunity to beat the virus is, seeing its share price hitting 484.47 on August 09, 2021. The company’s COVID vaccine success made the stock a big pandemic winner. There has yet to be a solution to defeat the virus once and for all, but one emerging NYSE company may have the answer and it’s trading at merely around $1!! NanoViricides Inc. (NYSE: NNVC) is a leading biopharmaceutical company that is developing nanotechnology-based antiviral therapeutics and has been working on a pan-coronavirus antiviral to fulfill an unmet medical need. This is a prime time to be watching the company as the [clinical trials of its broad-spectrum antiviral drug NV-CoV-2]( began on June 17, 2023, with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies. “We believe that the start of the Phase 1a/1b safety and efficacy clinical trial is an important milestone not only for NanoViricides and Karveer Meditech, India, but for the whole world," said Dr. Anil Diwan, Ph.D., President and Executive Chairman of the Company. On March 27, 2023 the Company entered into a License Agreement with Karveer Meditech, Pvt. Ltd., India, (Karveer) wherein the Company granted to Karveer a limited, non-transferable, exclusive license for the use, sale, or offer of sale in India of the Company's two clinical test drug candidates titled as NV-CoV-2 and NV-CoV-2-R for the treatment of COVID in patients in India. "NV-CoV-2 is aimed at satisfying the as-yet-unmet medical need for a highly effective broad-spectrum, pan-coronavirus drug that can be used for all patient populations. Further, we believe the nanoviricides technology adds a valuable tool to the basket of worldwide preparedness and response strategies for future viral pandemics,” added Dr. Diwan. The Clinical Trial Will Evaluate Both Safety and Initial Efficacy Indications in COVID patients:Phase 1a will assess the safety and tolerability of a new molecule (drug product NV-CoV-2 containing API NV-387) in healthy subjects. In Phase 1b, patients with mild to moderate COVID-19 will be enrolled to assess indication of efficacy. On July 6th NNVC announced that this clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing satisfactorily. There were no adverse events to date at any of the dose levels including the highest dosages! Effective treatments for COVID-19 remain very few and very limited in their capabilities, even after three years. Imagine a pan-coronavirus drug that is safe enough to be used by anyone and is highly effective remains an unmet medical need….. That’s what NNVC is developing and what could put this biotech company on the map! With its unique technology, NNVC has developed a strong R&D pipeline of many antiviral drugs. It’s no surprise that the company boasts [a $5.25 price target!]( This price target represents a +300%+ increase from current share prices! The stock also currently holds a “BUY” rating from [Investing.com]( and a “STAY LONG” rating from [AmericanBulls.com.]( This may be the most exciting time to be paying attention to NNVC. The company’s lead coronavirus drug candidate could become a game changer in fighting the virus and could quickly put NNVC at center stage! Make sure to watch for any developments on the clinical trial! [( NanoViricides, Inc. NYSE: NNVC Company Overview: NanoViricides, Inc. (NYSE: NNVC) is a development stage company moving to clinical-stage that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Their platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus and Ebola/Marburg viruses. NNVC has been a drug discovery company for many years while it has looked to perfect its patented nanoviricide technology, a platform technology that deploys a novel mechanism to combat viruses. What makes NNVC’s offerings so unique? Both NV-CoV-2 and NV-CoV-2-R have demonstrated pan-coronavirus, broad-spectrum effectiveness in pre-clinical studies. This broad-spectrum effectiveness indicates that SARS-CoV-2 variants that are continuously generated in the field are quite unlikely to escape either of these two drug candidates, a highly sought after characteristic for an antiviral drug! In contrast, the company notes that all of the existing antibodies and cocktails with emergency use approvals, including Evusheld, have lost effectiveness and have lost their emergency use authorizations (EUA) against the current SARS-CoV-2 Omicron variants. Paxlovid has limited application as it has been found to be effective only in adults over 65 years of age with co-morbidities, and its composition further limits its usefulness due to side effects and interactions with other drugs commonly taken by persons with co-morbidities. Molnupiravir is a known mutagen and its use is not recommended or severely restricted by international health authorities. Remdesivir is the only FDA approved drug for treating COVID, but it is only approved for hospitalized patients; it requires long, daily infusions, and clinically it has shown only marginal improvements, with reduction in hospital stay of a few days. NNVC’s NV-CoV-2 is poised to meet the unmet medical need of a highly effective and safe drug to treat COVID, and potentially long COVID with residual virus, that would be useable in all segments of patient populations, from children to otherwise healthy patients to older patients and patients with co-morbidities. The best part? NNVC’s drug may work against all current and future Covid variants! NV-CoV-2 is a broad-spectrum antiviral that looks to treat most human coronaviruses and will maintain its effectiveness as the variants mutate. This may mark a major step in the fight to find a permanent solution to COVID. Developing a drug that works against multiple COVID variants is key because as each variant mutates and spreads it has the [risk]( of further widespread outbreaks causing an endemic or even a future pandemic. NV-CoV-2 was found to work against many unrelated coronaviruses. So variants of SARS-CoV-2 (that causes COVID) are highly unlikely to be able to escape it! Additional Applications: NNVC is also exploring additional antiviral applications for NV-387, the active pharmaceutical ingredient used in NV-CoV-2, the Company's COVID clinical drug candidate. NV-387 has been found to have broad-spectrum activity against all of the tested seasonal coronaviruses and SARS-CoV-2 in pre-clinical studies. Antibiotics such as penicillin attack the bacterial surface and thereby kill the bacteria. Similarly, NV-387 is designed to attack the viral surface and destroy the virus particle. Similar to antibiotics that possess a broad-spectrum to treat bacterial infections, NV-387 could be a much needed broad-spectrum, direct acting, antiviral agent to treat multiple different viral infections. Having a safe and effective broad-spectrum antiviral agent such as NV-387 in hand would help combat future viral infection epidemics before they expand. This strategy should form a backbone of pandemic preparedness strategy, rather than reliance on vaccines and antibodies that have now been proven to be of limited durable utility. Additionally, once NV-387 based drug formulations such as NV-CoV-2 have undergone Phase I Safety/Tolerability study in humans, next antiviral applications or other indications of NV-387 are likely to be eligible for a much faster clinical pathway, possibly entering directly into Phase II/III clinical trials!! This would provide a substantial reduction in resource requirements and would significantly improve return on investments. NNVC is exploring in pre-clinical studies potential antiviral activity of NV-387 against other viruses, beginning with respiratory viruses. The company has initiated studies to treat Respiratory Syncytial Virus (RSV) infection. There is NO approved safe and effective drug for treatment of RSV in children, except that ribavirin, a highly toxic drug, is approved for use as a last resort. The markets addressed by NNVC’s drug programs are extremely large, into several tens of billions of dollars if not more! MORE REASONS TO HAVE [NNVC]( ON YOUR RADAR INCLUDE: - The company is led by the renowned inventor of nanoviricides technology, Dr. Anil Diwan, and is managed by a highly effective team who have decades of entrepreneurial, pharmaceutical, and nanomedicine experience. - - Strong P&E assets comprise the company’s cGMP-capable manufacturing and R&D facility. NNVC is one of a few biopharma companies that has its own cGMP-compliant manufacturing facility! - - The company’s drug products could significantly change the world if and they contend when hit the market. - Over 15+ years of experience in nanomedicine and antiviral therapy developments. - Fast moving drug candidate developments for the treatment of SARS-CoV-2 in patients. - A strong, diverse, and promising product pipeline that addresses the world’s most infamous and infectious viruses. - The antiviral therapy and nanomedicine market is expected to experience exponential growth in the coming years as more viruses emerge. - The company’s developments are sustainable beyond COVID-19 as their diverse product pipeline targets several markets simultaneously: In Summary… As COVID-19 continues to spread across the globe, increased demand for nanomedicine has led to the strong growth of the global nanomedicine market. Paying close attention to the biotech players with addressable solutions for big markets is what any savvy investor should be doing. AND ESPECIALLY WHEN THE COMPANY IS IN THE MISDT OF CLINICAL TRIALS! NNVC’s NV-CoV-2 addresses the unmet need for a safe and effective treatment with Covid-19 that can be used in otherwise healthy patients as well as in children, based on its strong safety and effectiveness observed in animal studies. With trials now underway, NNVC could quickly start gaining Wall Street attention and with a $5.25 price target, may see an upside in the TRIPLE DIGITS! Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in NNVC. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding NNVC with a start date of 7/11/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2023 | All rights reserved. [Unsubscribe](. [Twitter] [Facebook] [Instagram]